Design Therapeutics Inc expected to post a loss of 25  cents a share - Earnings Preview

Design Therapeutics

05/08/2022 18:01

* Design Therapeutics Inc  DSGN.OQ   DSGN.O  is expected
to show
no change in quarterly revenue when it reports  results on
August 8 (estimated). 
    * ​Refinitiv's mean analyst estimate for Design Therapeutics
Inc
is for a loss of 25 cents per share. For the same quarter last
year, the company reported a loss of 14 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Design
Therapeutics Inc is $30​, above​ its last closing price
of $20.90. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2022  -0.22       -0.22      -0.24     Missed  -9.1
 Dec. 31 2022  -0.25       -0.23      -0.20     Beat    11.8
 Sep. 30 2021  -0.14       -0.14      -0.21     Missed  -50​
 Jun. 30 2021  -0.18       -0.18      -0.14     Beat    23.6
 ​​Mar.        -0.07       -0.07      -0.31     Missed  -322.7
 31 2021                                                
                                                        ​
 This summary was machine generated August 5 at 17:01 GMT.  All
figures in US dollars  unless otherwise stated